1. Search Result
Search Result
Results for "

menin-mixed lineage leukemia interaction

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128347

    Epigenetic Reader Domain Inflammation/Immunology Cancer
    M-89 is a highly potent and specific menin inhibitor, with a Kd of 1.4 nM for binding to menin. M-89 inhibits the menin-mixed lineage leukemia (Menin-MLL) protein-protein interaction and has potential to study MLL leukemia. M-89 inhibits the cell growth in leukemia cell lines carrying MLL fusion .
    M‑89
  • HY-117948

    Epigenetic Reader Domain Cancer
    ML399 is a Menin-Mixed Lineage Leukemia (MLL) protein-protein interaction inhibitor.
    ML399
  • HY-12625

    Epigenetic Reader Domain Others
    MIV-6 is a small molecule inhibitor that inhibits menin-mixed lineage leukemia (MLL) interaction and exhibits strong selective activity in MLL leukemia cells with IC50 = 56 nM.
    MIV-6
  • HY-12625A

    Others Others
    MIV-6R is an optimized small molecule inhibitor of menin-mixed lineage leukemia (MLL) interaction with IC50 = 56 nM, and its specific mechanism of action activity has been validated in MLL leukemia cells.
    MIV-6R
  • HY-117948A

    Drug Isomer Epigenetic Reader Domain Cancer
    (S)-ML399 (Compound 18S) is the enantiomer of ML399 (HY-117948). (S)-ML399 acts as a Menin-MLL interaction inhibitor with an IC50 of 1400 nM. (S)-ML399 can be used to investigate acute leukemias with MLL translocations, including acute myeloid leukemia and acute lymphoblastic leukemia .
    (S)-ML399

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: